MTA1: A prognosis indicator of postoperative patients with esophageal carcinoma

Thoracic and Cardiovascular Surgeon

Volumn 61, Issue 6, 2013, Pages 479-485

  Song, Liang ^a   Wang, Zhou ^a   Liu, Xiangyan ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

esophageal neoplasms; lymphatic metastasis; metastasis associated gene 1; surgical procedures

Indexed keywords

ANTINEOPLASTIC AGENT; MTA1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGOGASTROSTOMY; ESOPHAGUS RESECTION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; CHINA; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HISTONE DEACETYLASES; HOSPITALS, UNIVERSITY; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; REPRESSOR PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84883867498     PISSN: 01716425     EISSN: 14391902     Source Type: Journal    
DOI: 10.1055/s-0032-1304545     Document Type: Article

References (26)

1. Chen G., Wang Z., Liu X. Y., Liu F. Y. Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Ivor-Lewis esophagectomy. World J Surg: 2007; 31 5 1107 1114 (Pubitemid 46716767)
2. Dresner S. M., Griffin S. M. Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy. Br J Surg: 2000; 87 10 1426 1433
3. Zhang M. Y., Wang Z., Liu X. Y., et al. The local control of radiotherapy following Ivor-Lewis esophagectomy in the patients with stage IIA middle-third thoracic esophageal cancer. Chinese Journal of Surgery: 2008; 46 1048 1050
4. Toh Y., Pencil S. D., Nicolson G. L. Analysis of the complete sequence of the novel metastasis-associated candidate gene, mta1, differentially expressed in mammary adenocarcinoma and breast cancer cell lines. Gene: 1995; 159 1 97 104
5. Li S-H, Wang Z., Liu X-Y. Metastasis-associated protein 1 (MTA1) overexpression is closely associated with shorter disease-free interval after complete resection of histologically node-negative esophageal cancer. World J Surg: 2009; 33 9 1876 1881
6. Li S. H., Tian H., Yue W. M., et al. Overexpression of metastasis-associated protein 1 is significantly correlated with tumor angiogenesis and poor survival in patients with early-stage non-small cell lung cancer. Ann Surg Oncol: 2011; 18 7 2048 2056
7. Wang Z., Liu X. Y., Liu F. Y., Chen J. H. [A study of correlation between early postoperative relapse with lymph node micrometastasis in patients with N0 esophageal cancer]. Zhonghua Wai Ke Za Zhi: 2004; 42 2 68 71
8. Tachibana M., Kinugasa S., Yoshimura H., Dhar D. K., Nagasue N. Extended esophagectomy with 3-field lymph node dissection for esophageal cancer. Arch Surg: 2003; 138 12 1383 1389, discussion 1390
9. Shields T. W. General Thoracic Surgery. Vol. 2. 5th ed. Philadelphia Lippincott Williams and Wilkins: 2000; 1905
10. Law S., Wong J. Two-field dissection is enough for esophageal cancer. Dis Esophagus: 2001; 14 2 98 103 (Pubitemid 32951977)
11. Wang Z., Liu X. Y., Liu F. Y., et al. Ivor-Lewis esophagectomy for treatment of esophageal cancer and Cox regression analysis of prognostic factors. Tumor: 2004; 24 3 286 289
12. Wang Z., Liu X. Y., Chen G., et al. The evaluation for therapeutic efficacy of the modified Ivor-Lewis surgery on squamous cell cancer in the middle-third thoracic esophagus. Chinese Journal of Clinical Oncology: 2006; 33 1012 1015
13. Kumar R., Wang R. A., Bagheri-Yarmand R. Emerging roles of MTA family members in human cancers. Semin Oncol: 2003; 30 5, Suppl 16 30 37 (Pubitemid 37433394)
14. Nicolson G. L., Nawa A., Toh Y., Taniguchi S., Nishimori K., Moustafa A. Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: role in epithelial cancer cell invasion, proliferation and nuclear regulation. Clin Exp Metastasis: 2003; 20 1 19 24 (Pubitemid 36308132)
15. Mazumdar A., Wang R. A., Mishra S. K., et al. Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol: 2001; 3 1 30 37 (Pubitemid 32114829)
16. Yan C., Wang H., Toh Y., Boyd D. D. Repression of 92-kDa type IV collagenase expression by MTA1 is mediated through direct interactions with the promoter via a mechanism, which is both dependent on and independent of histone deacetylation. J Biol Chem: 2003; 278 4 2309 2316 (Pubitemid 36801301)
17. Hofer M. D., Menke A., Genze F., Gierschik P., Giehl K. Expression of MTA1 promotes motility and invasiveness of PANC-1 pancreatic carcinoma cells. Br J Cancer: 2004; 90 2 455 462 (Pubitemid 38250645)
18. Jang K. S., Paik S. S., Chung H., Oh Y. H., Kong G. MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers. Cancer Sci: 2006; 97 5 374 379
19. Martin M. D., Hilsenbeck S. G., Mohsin S. K., et al. Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat: 2006; 95 1 7 12 (Pubitemid 43228076)
20. Hofer M. D., Kuefer R., Varambally S., et al. The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res: 2004; 64 3 825 829 (Pubitemid 38176879)
21. Balasenthil S., Broaddus R. R., Kumar R. Expression of metastasis-associated protein 1 (MTA1) in benign endometrium and endometrial adenocarcinomas. Hum Pathol: 2006; 37 6 656 661 (Pubitemid 43956542)
22. Ryu S. H., Chung Y. H., Lee H., et al. Metastatic tumor antigen 1 is closely associated with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma. Hepatology: 2008; 47 3 929 936 (Pubitemid 351449684)
23. Mahoney M. G., Simpson A., Jost M., et al. Metastasis-associated protein (MTA)1 enhances migration, invasion, and anchorage-independent survival of immortalized human keratinocytes. Oncogene: 2002; 21 14 2161 2170 (Pubitemid 34311370)
24. Toh Y., Nicolson G. L. The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clin Exp Metastasis: 2009; 26 3 215 227
25. Qian H., Lu N., Xue L., et al. Reduced MTA1 expression by RNAi inhibits in vitro invasion and migration of esophageal squamous cell carcinoma cell line. Clin Exp Metastasis: 2005; 22 8 653 662 (Pubitemid 44259526)
26. Toh Y., Kuwano H., Mori M., Nicolson G. L., Sugimachi K. Overexpression of metastasis-associated MTA1 mRNA in invasive oesophageal carcinomas. Br J Cancer: 1999; 79 11-12 1723 1726 (Pubitemid 29132295)